Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy.

Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, Chapman JD, Eckelman WC, Fyles AW, Giaccia AJ, Hill RP, Koch CJ, Krishna MC, Krohn KA, Lewis JS, Mason RP, Melillo G, Padhani AR, Powis G, Rajendran JG, Reba R, Robinson SP, Semenza GL, Swartz HM, Vaupel P, Yang D, Croft B, Hoffman J, Liu G, Stone H, Sullivan D.

Int J Radiat Biol. 2006 Oct;82(10):699-757. Review.

PMID:
17118889
2.

Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use.

Pastorek J, Pastorekova S.

Semin Cancer Biol. 2015 Apr;31:52-64. doi: 10.1016/j.semcancer.2014.08.002. Review.

PMID:
25117006
3.

Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?

Vordermark D, Brown JM.

Strahlenther Onkol. 2003 Dec;179(12):801-11. Review.

PMID:
14652668
4.

Cancer-associated carbonic anhydrases and their inhibition.

Pastorekova S, Zatovicova M, Pastorek J.

Curr Pharm Des. 2008;14(7):685-98. Review.

PMID:
18336315
5.

Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies.

Bache M, Kappler M, Said HM, Staab A, Vordermark D.

Curr Med Chem. 2008;15(4):322-38. Review.

PMID:
18288988
6.

Modulation of carbonic anhydrase 9 (CA9) in human brain cancer.

Said HM, Supuran CT, Hageman C, Staab A, Polat B, Katzer A, Scozzafava A, Anacker J, Flentje M, Vordermark D.

Curr Pharm Des. 2010;16(29):3288-99. Review.

PMID:
20819065
7.

Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium.

Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, Ree AH, Flatmark K, Lyng H, Calzada MJ, Peso LD, Landazuri MO, Görlach A, Flamm H, Kieninger J, Urban G, Weltin A, Singleton DC, Haider S, Buffa FM, Harris AL, Scozzafava A, Supuran CT, Moser I, Jobst G, Busk M, Toustrup K, Overgaard J, Alsner J, Pouyssegur J, Chiche J, Mazure N, Marchiq I, Parks S, Ahmed A, Ashcroft M, Pastorekova S, Cao Y, Rouschop KM, Wouters BG, Koritzinsky M, Mujcic H, Cojocari D.

J Enzyme Inhib Med Chem. 2015;30(5):689-721. doi: 10.3109/14756366.2014.966704. Review.

PMID:
25347767
8.

The role of carbonic anhydrase IX in hypoxia control in OSCC.

Pérez-Sayáns M, Supuran CT, Pastorekova S, Suárez-Peñaranda JM, Pilar GD, Barros-Angueira F, Gándara-Rey JM, García-García A.

J Oral Pathol Med. 2013 Jan;42(1):1-8. doi: 10.1111/j.1600-0714.2012.01144.x. Review.

PMID:
22417164
9.

Endogenous hypoxia markers in locally advanced cancers of the uterine cervix: reality or wishful thinking?

Mayer A, Höckel M, Vaupel P.

Strahlenther Onkol. 2006 Sep;182(9):501-10. Review.

PMID:
16944371
10.

Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia.

Kizaka-Kondoh S, Konse-Nagasawa H.

Cancer Sci. 2009 Aug;100(8):1366-73. doi: 10.1111/j.1349-7006.2009.01195.x. Review.

11.

Hypoxia in head and neck cancer: how much, how important?

Janssen HL, Haustermans KM, Balm AJ, Begg AC.

Head Neck. 2005 Jul;27(7):622-38. Review.

PMID:
15952198
12.

Measurement of tumor hypoxia using single-cell methods.

Olive PL, Aquino-Parsons C.

Semin Radiat Oncol. 2004 Jul;14(3):241-8. Review.

PMID:
15254867
13.

Inhibition of carbonic anhydrase IX: a new strategy against cancer.

Winum JY, Scozzafava A, Montero JL, Supuran CT.

Anticancer Agents Med Chem. 2009 Jul;9(6):693-702. Review.

PMID:
19601749
14.

Is carbonic anhydrase IX a validated target for molecular imaging of cancer and hypoxia?

Li J, Zhang G, Wang X, Li XF.

Future Oncol. 2015;11(10):1531-41. doi: 10.2217/fon.15.11. Review.

15.

Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.

Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA.

Clin Cancer Res. 2003 Oct 15;9(13):4641-52. Review.

16.

Hypoxia-inducible factors in OSCC.

Pérez-Sayáns M, Suárez-Peñaranda JM, Pilar GD, Barros-Angueira F, Gándara-Rey JM, García-García A.

Cancer Lett. 2011 Dec 26;313(1):1-8. doi: 10.1016/j.canlet.2011.08.017. Review.

PMID:
21959110
17.
18.

Carbonic anhydrase IX: a new druggable target for the design of antitumor agents.

Winum JY, Rami M, Scozzafava A, Montero JL, Supuran C.

Med Res Rev. 2008 May;28(3):445-63. Review.

PMID:
17880011
19.

Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers.

Bussink J, Kaanders JH, van der Kogel AJ.

Radiother Oncol. 2003 Apr;67(1):3-15. Review.

PMID:
12758235
20.

Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis.

Jubb AM, Buffa FM, Harris AL.

J Cell Mol Med. 2010 Jan;14(1-2):18-29. doi: 10.1111/j.1582-4934.2009.00944.x. Review.

Items per page

Supplemental Content

Support Center